Kintor Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Kintor Pharmaceutical has a total shareholder equity of CN¥391.6M and total debt of CN¥234.3M, which brings its debt-to-equity ratio to 59.8%. Its total assets and total liabilities are CN¥739.5M and CN¥348.0M respectively.
Key information
59.8%
Debt to equity ratio
CN¥234.30m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥333.77m |
| Equity | CN¥391.58m |
| Total liabilities | CN¥347.97m |
| Total assets | CN¥739.54m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KNTP.F's short term assets (CN¥371.4M) exceed its short term liabilities (CN¥238.3M).
Long Term Liabilities: KNTP.F's short term assets (CN¥371.4M) exceed its long term liabilities (CN¥109.7M).
Debt to Equity History and Analysis
Debt Level: KNTP.F has more cash than its total debt.
Reducing Debt: KNTP.F's debt to equity ratio has increased from 19.9% to 59.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KNTP.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KNTP.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.2% each year